Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Purchased by Arizona State Retirement System

Arizona State Retirement System raised its holdings in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) by 8.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,826 shares of the biotechnology company’s stock after acquiring an additional 1,528 shares during the quarter. Arizona State Retirement System’s holdings in Rocket Pharmaceuticals were worth $249,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. SG Americas Securities LLC increased its stake in shares of Rocket Pharmaceuticals by 796.2% during the 4th quarter. SG Americas Securities LLC now owns 54,921 shares of the biotechnology company’s stock worth $690,000 after purchasing an additional 48,793 shares in the last quarter. Jennison Associates LLC grew its holdings in Rocket Pharmaceuticals by 72.6% during the 4th quarter. Jennison Associates LLC now owns 70,304 shares of the biotechnology company’s stock valued at $884,000 after buying an additional 29,564 shares during the last quarter. Mirador Capital Partners LP increased its position in Rocket Pharmaceuticals by 403.9% during the fourth quarter. Mirador Capital Partners LP now owns 84,529 shares of the biotechnology company’s stock worth $1,063,000 after buying an additional 67,755 shares in the last quarter. First Turn Management LLC raised its holdings in shares of Rocket Pharmaceuticals by 10.8% in the third quarter. First Turn Management LLC now owns 621,306 shares of the biotechnology company’s stock worth $11,476,000 after acquiring an additional 60,317 shares during the last quarter. Finally, Sovran Advisors LLC purchased a new stake in shares of Rocket Pharmaceuticals in the fourth quarter valued at $1,895,000. Institutional investors and hedge funds own 98.39% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on RCKT shares. Needham & Company LLC cut their target price on shares of Rocket Pharmaceuticals from $52.00 to $42.00 and set a “buy” rating for the company in a research note on Friday, February 28th. Scotiabank boosted their price objective on shares of Rocket Pharmaceuticals from $51.00 to $52.00 and gave the company a “sector outperform” rating in a research report on Monday, March 3rd. Jefferies Financial Group initiated coverage on shares of Rocket Pharmaceuticals in a research report on Wednesday, December 18th. They set a “buy” rating and a $29.00 target price on the stock. Wedbush assumed coverage on shares of Rocket Pharmaceuticals in a report on Monday, December 30th. They set an “outperform” rating and a $32.00 price objective on the stock. Finally, BMO Capital Markets began coverage on shares of Rocket Pharmaceuticals in a research report on Wednesday. They set an “outperform” rating and a $50.00 price target for the company. One equities research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $43.00.

Rocket Pharmaceuticals Stock Up 3.1 %

Shares of Rocket Pharmaceuticals stock opened at $8.76 on Friday. Rocket Pharmaceuticals, Inc. has a twelve month low of $8.06 and a twelve month high of $28.67. The stock has a market cap of $934.08 million, a price-to-earnings ratio of -3.19 and a beta of 1.03. The company has a current ratio of 6.05, a quick ratio of 6.05 and a debt-to-equity ratio of 0.06. The company has a fifty day moving average price of $10.22 and a 200 day moving average price of $13.97.

Rocket Pharmaceuticals (NASDAQ:RCKT) last issued its earnings results on Monday, March 3rd. The biotechnology company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.06. Equities research analysts forecast that Rocket Pharmaceuticals, Inc. will post -2.83 earnings per share for the current fiscal year.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.